Presenting the news at a press conference at the in-cosmetics trade show, Ashland showed in vitro that its technology boosts endogenous synthesis of coenzyme Q10, the powerful antioxidant recognized as an effective ingredient against premature skin aging.
The US-based company carried out a double-blind clinical study against a placebo cream showing that Ashland’s Peptide Q10 biofunctional helps to reduce facial wrinkles and fine lines when used at just 0.5 percent concentration.
According to Ashland, the new technology represents a breakthrough alternative to traditional application of coenzyme Q10, where external delivery may not fully restore this lipid-soluble substance within the epidermal layer of skin.
“In rethinking CoQ10 with a biological approach, Peptide Q10 biofunctional represents a major boost in anti-aging skin care formulating, a truly viable strategy for countering the age-related decline of endogenous CoQ10,” said Joel Mantelin, global marketing director, Skin Care, Care Specialties, Ashland Specialty Ingredients.
“This ingredient is a complementary, anti-aging skin care strategy to traditional application of coenzyme Q10,” he said.
According to Mantelin, addressing an age-related decline in coenzyme Q10 levels with a peptide bioengineered specifically for creams and lotions will serve as the basis for many innovative product forms.
“It is estimated that CoQ10 levels may diminish with aging by as much as 75 percent in the epidermis of people between the ages of 30 and 80,” he explained.
“This dramatic decline is known to handicap the antioxidant defense capability of cells and impede their ability to produce energy.”
“With a peptide bioengineered to help boost endogenous synthesis of coenzyme Q10 in vitro, formulators of skin creams and lotions now have the capability to formulate products with distinct benefits, such as CoQ10 booster, antioxidant builder and as a tool to minimize the appearance of wrinkles and fine lines.”